These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 12869396)

  • 1. Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers.
    Kelloff GJ; O'Shaughnessy JA; Gordon GB; Hawk ET; Sigman CC
    Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):593-6. PubMed ID: 12869396
    [No Abstract]   [Full Text] [Related]  

  • 2. Point: Surrogate end point biomarkers are likely to be limited in their usefulness in the development of cancer chemoprevention agents against sporadic cancers.
    Armstrong WB; Taylor TH; Meyskens FL
    Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):589-92. PubMed ID: 12869395
    [No Abstract]   [Full Text] [Related]  

  • 3. Surrogate endpoint biomarkers for phase II cancer chemoprevention trials.
    Kelloff GJ; Boone CW; Crowell JA; Steele VE; Lubet R; Doody LA
    J Cell Biochem Suppl; 1994; 19():1-9. PubMed ID: 7823579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surrogate end-point biomarkers in chemopreventive drug development.
    Kelloff GJ; Sigman CC; Hawk ET; Johnson KM; Crowell JA; Guyton KZ
    IARC Sci Publ; 2001; 154():13-26. PubMed ID: 11220652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers and surrogacy: relevance to chemoprevention.
    Kensler TW; Davidson NE; Groopman JD; Muñoz A
    IARC Sci Publ; 2001; 154():27-47. PubMed ID: 11220666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer.
    Kelloff GJ; Sigman CC; Johnson KM; Boone CW; Greenwald P; Crowell JA; Hawk ET; Doody LA
    Cancer Epidemiol Biomarkers Prev; 2000 Feb; 9(2):127-37. PubMed ID: 10698472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of surrogate endpoint biomarkers for clinical trials of cancer chemopreventive agents: relationships to fundamental properties of preinvasive (intraepithelial) neoplasia.
    Boone CW; Kelloff GJ
    J Cell Biochem Suppl; 1994; 19():10-22. PubMed ID: 7823580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing the power of surrogate endpoint biomarkers: the aggregation of predictive factors.
    Burke HB
    J Cell Biochem Suppl; 1994; 19():278-82. PubMed ID: 7823601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Summary of recommendations for colonic biomarker studies of candidate chemopreventive compounds in phase II clinical trials.
    Lipkin M
    J Cell Biochem Suppl; 1994; 19():94-8. PubMed ID: 7823612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The convergent development of molecular-targeted drugs for cancer treatment and prevention.
    Lippman SM; Heymach JV
    Clin Cancer Res; 2007 Jul; 13(14):4035-41. PubMed ID: 17634526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protocol design considerations that relate to demonstrating the safety and effectiveness of chemopreventive agents.
    Johnson KA; Beitz J; Justice R; Schmidt W; Andrews P; DeLap R
    J Cell Biochem Suppl; 1997; 27():1-6. PubMed ID: 9591186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A checklist for suitability of biomarkers as surrogate endpoints in chemoprevention of breast cancer.
    Bogoch S; Bogoch ES
    J Cell Biochem Suppl; 1994; 19():173-85. PubMed ID: 7823589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant crypt foci and beta-catenin accumulated crypts; significance and roles for colorectal carcinogenesis.
    Mori H; Yamada Y; Kuno T; Hirose Y
    Mutat Res; 2004 May; 566(3):191-208. PubMed ID: 15082237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical development plan: dehydroepiandrosterone (DHEA).
    J Cell Biochem Suppl; 1996; 26():86-99. PubMed ID: 9154170
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical development plan: vitamin A.
    J Cell Biochem Suppl; 1996; 26():269-307. PubMed ID: 9154183
    [No Abstract]   [Full Text] [Related]  

  • 16. A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity.
    Stearns V; Gallagher A; Kleer CG; Singh B; Freedman M; Haddad BR; Isaacs C; Warren R; Brown M; Cullen J; Trock B; Hayes DF
    Clin Cancer Res; 2004 Dec; 10(24):8332-40. PubMed ID: 15623610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronicles in drug discovery.
    Moral MA; Khurdayan VK; Bozzo J
    Drug News Perspect; 2006 Oct; 19(8):485-9. PubMed ID: 17160149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. If there is gold in the labeling index hills, are we digging in the right place?
    Aickin M
    J Cell Biochem Suppl; 1994; 19():91-3. PubMed ID: 7823611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical development plan: genistein.
    J Cell Biochem Suppl; 1996; 26():114-26. PubMed ID: 9154172
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical development plan: phenethyl isothiocyanate.
    J Cell Biochem Suppl; 1996; 26():149-57. PubMed ID: 9154175
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.